

genOway announces capacity expansion at new facilities

Lyon, France, May 30th: genOway (Alternext-NYSE Euronext: ALGEN; ISIN: FR0004053510), the biotechnology company dedicated to the design and development of genetically modified models, is celebrating the purchase of brand new laboratory located in Lyon Biopole-Techsud with operation beginning in early 2018. This significant expansion of capacity showcases the fruit of genOway's investment in growth that will greatly enhance its service and production capabilities.

Alexandre Fraichard, General Manager at genOway: *"It shows our increased investment in our physical facilities and effort to uphold our commitment of bringing leading edge solutions to our customers in academic and biopharmaceutical research. This is another milestone of our path horizon 2018 to double service and production capacity."*

About genOway

genOway is a biotechnology company designing and developing research models for the bio-pharmaceutical, chemical, agrochemical and food industries as well as for academic research. With highly qualified scientific personnel, the company has a workforce of 105 people and operates in 28 countries in Europe, Asia and North America, serving clients in 265 academic institutions, 70 biopharmaceutical and 14 of the Top 20 pharma companies. It is a market leader in terms of both size and customer portfolios. The company's development is founded upon a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed contracts with leaders of the pharmaceutical industry, and with prestigious academic research centers.

For more information, visit our web site <http://www.genoway.com>